Xingxiang Pu

1.8k total citations
76 papers, 1.0k citations indexed

About

Xingxiang Pu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Xingxiang Pu has authored 76 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in Xingxiang Pu's work include Lung Cancer Treatments and Mutations (29 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (16 papers). Xingxiang Pu is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (16 papers). Xingxiang Pu collaborates with scholars based in China, United States and Hong Kong. Xingxiang Pu's co-authors include Guoliang Huang, Hongqiang Guo, Lin Wu, Ying Tian, Haoran Li, Chengcheng Guo, Li Jiang, Ye Shen, Qianzhi Wang and Kang Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Xingxiang Pu

65 papers receiving 1.0k citations

Peers

Xingxiang Pu
Andreas Varkaris United States
Yuho Maki Japan
Kunitoshi Shigeyasu Japan
Kevin Zarrabi United States
Jacinth Wing‐Sum Cheu Hong Kong
Wenting Liao China
Anna Truini Italy
Ashwini A. Katre United States
Seon Ye Kim South Korea
Shengjia Shi China
Andreas Varkaris United States
Xingxiang Pu
Citations per year, relative to Xingxiang Pu Xingxiang Pu (= 1×) peers Andreas Varkaris

Countries citing papers authored by Xingxiang Pu

Since Specialization
Citations

This map shows the geographic impact of Xingxiang Pu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingxiang Pu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingxiang Pu more than expected).

Fields of papers citing papers by Xingxiang Pu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xingxiang Pu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingxiang Pu. The network helps show where Xingxiang Pu may publish in the future.

Co-authorship network of co-authors of Xingxiang Pu

This figure shows the co-authorship network connecting the top 25 collaborators of Xingxiang Pu. A scholar is included among the top collaborators of Xingxiang Pu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xingxiang Pu. Xingxiang Pu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luo, Haowen, et al.. (2025). Effects of Selenium Nanoparticle Application on Flavor Volatiles of Aromatic Rice. Foods. 14(4). 552–552. 1 indexed citations
2.
3.
Xiong, Guang, Sheng Wu, Puxian Xiong, et al.. (2025). SrAl 2 O 4 : Eu 2+ , Dy 3+ mechanoluminescent phosphor for potential bearings stress distribution imaging. Journal of the American Ceramic Society. 108(7). 1 indexed citations
4.
Deng, Jinhai, Xingxiang Pu, Tingting Yuan, et al.. (2025). PAM-Independent CRISPR-Cas12a System for Specific Assays of Single Nucleotide Variants. JACS Au. 5(3). 1392–1401. 9 indexed citations
5.
Pu, Xingxiang, Jia Li, Yan Xu, et al.. (2025). Potential biomarkers of primary resistance to first- and second-generation EGFR-TKIs in non-small-cell lung cancer: a real-world study. Therapeutic Advances in Medical Oncology. 17. 22781368–22781368. 2 indexed citations
6.
Wu, Fan, Peng Yuan, Yulan Zeng, et al.. (2024). 101P Circulating tumor DNA minimal residual disease predicts the risk of progression after long-term response to first-line immunotherapy in advanced NSCLC. Annals of Oncology. 35. S254–S254. 1 indexed citations
7.
Liu, Bin, Xingxiang Pu, Lin Wu, et al.. (2024). A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 2534–2534. 1 indexed citations
8.
9.
Zeng, Yue, Xingxiang Pu, Fengjiao He, et al.. (2024). The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma. iScience. 27(7). 110219–110219.
10.
Pu, Xingxiang, Juan Li, Bo Zhang, et al.. (2024). Efficacy in patients with EGFR -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050. Future Oncology. 20(37). 2971–2982. 2 indexed citations
11.
Kong, Yi Wen, Fan Tong, Ruiguang Zhang, et al.. (2024). Role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study. Chinese Medical Journal. 138(17). 2130–2138. 1 indexed citations
12.
Zhai, Wei, Wensheng Yang, Xuelian Xiao, et al.. (2024). ADAMTS4 exacerbates lung cancer progression via regulating c-Myc protein stability and activating MAPK signaling pathway. Biology Direct. 19(1). 94–94.
13.
Dong, Xiaorong, Fan Tong, Yunyi Kong, et al.. (2023). EP13.07-09 The Role of Radiotherapy in Extensive-Stage Small Cell Lung Cancer after Durvalumab-Based Immunochemotherapy: A Retrospective Study. Journal of Thoracic Oncology. 18(11). S710–S710.
14.
Liu, Quan, Meng Chen, Lichun Deng, et al.. (2022). Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial. Translational Lung Cancer Research. 11(5). 832–844. 8 indexed citations
15.
Wang, Wenxian, Xiaodong Gu, Liping Wang, et al.. (2021). The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. Cancer Immunology Immunotherapy. 71(7). 1693–1703. 35 indexed citations
16.
Lei, Lei, Wenxian Wang, You‐cai Zhu, et al.. (2020). Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non- small cell lung cancer patients: a multicenter retrospective study. Translational Cancer Research. 9(10). 6039–6049. 2 indexed citations
17.
Yan, Xiang, Xiaoshan Zhang, Li Wang, et al.. (2018). Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. Cancer Research. 79(1). 125–132. 62 indexed citations
18.
Jia, Wenrui, Fei Bai, Rui Zhong, et al.. (2018). Association of microRNA-423 rs6505162 C>A polymorphism with susceptibility and metastasis of colorectal carcinoma. Medicine. 97(6). e9846–e9846. 15 indexed citations
19.
Wu, Lin, Xingxiang Pu, Qianzhi Wang, et al.. (2015). miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9. Oncology Letters. 11(2). 945–952. 50 indexed citations
20.
Liao, Dan, Xingxiang Pu, Hua Chen, et al.. (2014). Cyclin D1 G870A Polymorphism and Risk of Nasopharyngeal Carcinoma: A Case-Control Study and Meta-Analysis. PLoS ONE. 9(11). e113299–e113299. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andreas Varkaris Breakdown of academic impact, for papers by Yuho Maki Breakdown of academic impact, for papers by Kunitoshi Shigeyasu Breakdown of academic impact, for papers by Kevin Zarrabi Breakdown of academic impact, for papers by Jacinth Wing‐Sum Cheu Breakdown of academic impact, for papers by Wenting Liao Breakdown of academic impact, for papers by Anna Truini Breakdown of academic impact, for papers by Ashwini A. Katre Breakdown of academic impact, for papers by Seon Ye Kim Breakdown of academic impact, for papers by Shengjia Shi
Rankless by CCL
2026